Yesterday, March 16, 2016, 100 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $51.12 to $7,757,838.42.

Highlighted Stocks Traded by Insiders:

CoreSite Realty (COR) - FREE Research Report

Finnin Jeffrey S, who is CFO and Treasurer at CoreSite Realty, sold 4,000 shares at $67.00 on March 16, 2016. Following this transaction, the CFO and Treasurer owned 130,439 shares meaning that the stake was reduced by 2.98% with the 4,000-share transaction.

The shares most recently traded at $66.36, down $0.64, or 0.96% since the insider transaction. Historical insider transactions for CoreSite Realty go as follows:

  • 4-Week # shares bought: 3,000
  • 4-Week # shares sold: 20,510
  • 12-Week # shares bought: 3,000
  • 12-Week # shares sold: 20,510
  • 24-Week # shares bought: 3,000
  • 24-Week # shares sold: 36,689

The average volume for CoreSite Realty has been 392,000 shares per day over the past 30 days. CoreSite Realty has a market cap of $2.0 billion and is part of the financial sector and real estate industry. Shares are up 17.44% year-to-date as of the close of trading on Wednesday.

CoreSite Realty Corporation engages in the ownership, acquisition, construction, and management of data centers. The stock currently has a dividend yield of 3.21%. The company has a P/E ratio of 64.2. Currently, there are 5 analysts who rate CoreSite Realty a buy, no analysts rate it a sell, and 3 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on COR - FREE

TheStreet Quant Ratings rates CoreSite Realty as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, impressive record of earnings per share growth, compelling growth in net income, good cash flow from operations and expanding profit margins. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook. Get the full CoreSite Realty Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Ciena (CIEN) - FREE Research Report

Alexander Stephen B, who is Sr VP Chief Technology Officer at Ciena, sold 3,500 shares at $17.38 on March 16, 2016. Following this transaction, the Sr VP Chief Technology Officer owned 159,535 shares meaning that the stake was reduced by 2.15% with the 3,500-share transaction.

Frodsham James, who is SR. VP, Chief Strategy Officer at Ciena, sold 4,000 shares at $17.38 on March 16, 2016. Following this transaction, the SR. VP, Chief Strategy Officer owned 166,910 shares meaning that the stake was reduced by 2.34% with the 4,000-share transaction.

The shares most recently traded at $17.31, down $0.07, or 0.4% since the insider transaction. Historical insider transactions for Ciena go as follows:

  • 4-Week # shares bought: 5,000
  • 4-Week # shares sold: 5,800
  • 12-Week # shares bought: 5,000
  • 12-Week # shares sold: 20,300
  • 24-Week # shares bought: 5,000
  • 24-Week # shares sold: 308,953

The average volume for Ciena has been 3.6 million shares per day over the past 30 days. Ciena has a market cap of $2.3 billion and is part of the technology sector and telecommunications industry. Shares are down 16.48% year-to-date as of the close of trading on Wednesday.

Ciena Corporation provides equipment, software, and services that support the transport, switching, aggregation, service delivery, and management of voice, video, and data traffic on communications networks worldwide. The company has a P/E ratio of 89.1. Currently, there are 14 analysts who rate Ciena a buy, no analysts rate it a sell, and 1 rates it a hold.

Exclusive Offer: Get the latest Stock Analysis on CIEN - FREE

TheStreet Quant Ratings rates Ciena as a hold. The company's strengths can be seen in multiple areas, such as its revenue growth, impressive record of earnings per share growth and compelling growth in net income. However, as a counter to these strengths, we also find weaknesses including a generally disappointing performance in the stock itself, weak operating cash flow and generally higher debt management risk. Get the full Ciena Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Chimerix (CMRX) - FREE Research Report

Mario Ernest, who is Director at Chimerix, bought 25,000 shares at $5.06 on March 16, 2016. Following this transaction, the Director owned 292,919 shares meaning that the stake was boosted by 9.33% with the 25,000-share transaction.

The shares most recently traded at $5.10, up $0.04, or 0.76% since the insider transaction. Historical insider transactions for Chimerix go as follows:

  • 4-Week # shares bought: 20,000
  • 4-Week # shares sold: 122,950
  • 12-Week # shares bought: 155,000
  • 12-Week # shares sold: 122,950
  • 24-Week # shares bought: 155,000
  • 24-Week # shares sold: 122,950

The average volume for Chimerix has been 4.3 million shares per day over the past 30 days. Chimerix has a market cap of $234.6 million and is part of the health care sector and drugs industry. Shares are down 44.92% year-to-date as of the close of trading on Wednesday.

Chimerix, Inc., a biopharmaceutical company, discovers, develops, and commercializes oral antivirals in the areas of unmet medical needs in the United States. Currently, there is 1 analyst who rates Chimerix a buy, 1 analyst rates it a sell, and 7 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on CMRX - FREE

TheStreet Quant Ratings rates Chimerix as a sell. The company's weaknesses can be seen in multiple areas, such as its feeble growth in its earnings per share, deteriorating net income, disappointing return on equity, weak operating cash flow and generally disappointing historical performance in the stock itself. Get the full Chimerix Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.